LINKÖPING, Sweden – AMRA Medical is pleased to announce the publication of new research in Neurology demonstrating the potential of quantitative whole-body MRI to measure disease progression in Spinal and Bulbar Muscular Atrophy (SBMA), a rare, progressive neuromuscular disease. The research was also selected for the cover of the issue, providing...

SYDNEY, Australia — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new data showing its lead asset, paxalisib, achieved a 100% clinical benefit rate in six evaluable patients with Stage IV triple-negative breast...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J. — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China National Medical Products Administration (“NMPA”) for the treatment...